Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.55 |
| ▸ | REN | P00797 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19405101 | 0.93 | TDP1 (0.69) | POLBAPEX1TDP1CNR2REN | |
| SCHEMBL195224 | 0.89 | LMNA (0.58) | CNR2RENLMNAALDH1A1 | |
| SCHEMBL2721394 | 0.88 | REN (0.69) | POLBAPEX1TDP1CNR2REN | |
| SCHEMBL13185665 | 0.88 | REN (0.51) | POLBAPEX1TDP1CNR2REN | |
| SCHEMBL13191459 | 0.86 | POLB (0.57) | POLBAPEX1TDP1CNR2REN | |
| SCHEMBL12801514 | 0.86 | REN (0.50) | POLBAPEX1TDP1CNR2REN | |
| SCHEMBL14817946 | 0.86 | POLB (0.65) | POLBAPEX1TDP1CNR2ALOX5 | |
| SCHEMBL7080194 | 0.84 | POLB (0.63) | POLBAPEX1TDP1CNR2LMNA | |
| SCHEMBL3456186 | 0.84 | LMNA (0.68) | CNR2RENLMNAALDH1A1 | |
| SCHEMBL19488860 | 0.83 | POLB (0.54) | POLBAPEX1TDP1CNR2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
| US-7745484-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | POLB 1966/4885APEX1 3386/4885TDP1 961/4885 |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | POLB 1966/4885APEX1 3386/4885TDP1 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.